Search

everythinglearnresearchcommunity

for

Search:↓

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Neofollics lotion is discussed as a hair loss treatment, but users report it is ineffective and not supported by strong evidence. Users suggest sticking to FDA-approved treatments like Minoxidil and Finasteride.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

Topical finasteride in Europe is often seen as less effective than oral forms, with users suggesting alternative application methods for better results. Many prefer oral finasteride due to cost and effectiveness.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

The conversation discusses microneedling techniques and the use of Minoxidil, copper peptides, EGF, FGF, ceramides, and hydration serums to enhance hair growth. It explores optimizing scalp conditions and the potential benefits of various compounds in conjunction with microneedling.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

The conversation is about using DIY copper peptide (GHK CU) serum for microneedling to address hair loss, with additional treatments including Nizoral for DHT reduction and red light therapy. The user is considering adding Minoxidil but is concerned due to having cats.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.